| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
29,655 |
27,828 |
$5.09M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
11,161 |
10,477 |
$2.14M |
| S9083 |
Global fee urgent care centers |
11,347 |
10,703 |
$1.52M |
| 99215 |
Prolong outpt/office vis |
7,512 |
7,093 |
$1.30M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
30,928 |
29,514 |
$534K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
36,917 |
26,725 |
$477K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,851 |
2,658 |
$408K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,720 |
1,612 |
$293K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
21,096 |
20,293 |
$267K |
| 71046 |
Radiologic examination, chest; 2 views |
4,108 |
3,916 |
$259K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
797 |
755 |
$147K |
| 99205 |
Prolong outpt/office vis |
878 |
834 |
$141K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,300 |
2,104 |
$132K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,404 |
1,341 |
$131K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
757 |
717 |
$111K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,272 |
2,080 |
$110K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,323 |
2,179 |
$71K |
| 73610 |
|
332 |
304 |
$45K |
| 94664 |
|
2,094 |
1,878 |
$36K |
| 84703 |
|
462 |
432 |
$20K |
| 74019 |
|
307 |
289 |
$19K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
991 |
939 |
$19K |
| 73630 |
|
235 |
220 |
$15K |
| 81001 |
|
2,634 |
2,475 |
$14K |
| 73110 |
|
83 |
79 |
$10K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
461 |
406 |
$8K |
| 87581 |
|
1,470 |
1,406 |
$8K |
| 73140 |
|
278 |
256 |
$7K |
| 85027 |
|
355 |
332 |
$6K |
| 73564 |
|
92 |
90 |
$6K |
| 80047 |
|
30 |
29 |
$5K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
18 |
18 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
533 |
514 |
$4K |
| 87807 |
|
670 |
629 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,777 |
1,693 |
$3K |
| 12011 |
|
14 |
14 |
$2K |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
12 |
12 |
$2K |
| 87045 |
|
24 |
24 |
$2K |
| 87077 |
|
340 |
318 |
$1K |
| 29130 |
|
49 |
43 |
$1K |
| 74018 |
|
28 |
28 |
$941.36 |
| 87486 |
|
968 |
924 |
$837.73 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
162 |
158 |
$474.42 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,395 |
1,307 |
$456.54 |
| 29125 |
|
13 |
13 |
$414.42 |
| 29515 |
|
44 |
39 |
$216.29 |
| 73130 |
|
42 |
41 |
$176.90 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
69 |
55 |
$22.31 |
| 85007 |
|
318 |
294 |
$0.00 |
| 51701 |
|
51 |
46 |
$0.00 |
| 87186 |
|
268 |
251 |
$0.00 |
| 85014 |
|
29 |
28 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
114 |
110 |
$0.00 |
| 87040 |
|
27 |
27 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
82 |
81 |
$0.00 |
| 86140 |
|
12 |
12 |
$0.00 |